FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma

Podcast | English | 2024 | 22 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study.

Podcast Hosts:

Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Ibiayi Dagogo-Jack, MD, Thoracic Oncoligist, Instructor of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Quincy Chu, MD, Thoracic Oncologist, University of Alberta Cross Cancer Institute's Drug Development Program, CCTG Investigational New Drug Committee Chair, Edmonton, Alberta, Canada